March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Design and Optimization of a Transscleral Iontophoresis Applicator for Delivering Biologics to the Anterior and Posterior Segments
Author Affiliations & Notes
  • Michael Manzo
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Peyman Moslemy
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Begona Ruiz-Perez
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Fengqui Fan
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Lydia Mbocha
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Will Schubert
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Phil Isom
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Tracy Dowie
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Pammy Subramony
    Eyegate Pharmaceuticals Inc, Waltham, Massachusetts
  • Michael A. Patane
    EyeGate Pharmaceuticals, Inc, Waltham, Massachusetts
  • Footnotes
    Commercial Relationships  Michael Manzo, Eyegate Pharmaceuticals Inc (E); Peyman Moslemy, Eyegate Pharmaceuticals (E); Begona Ruiz-Perez, Eyegate Pharmaceuticals (E); Fengqui Fan, Eyegate Pharmaceuticals (E); Lydia Mbocha, Eyegate Pharmaceuticals (E); Will Schubert, Eyegate Pharmaceuticals (E); Phil Isom, Eyegate Pharmaceuticals (E); Tracy Dowie, Eyegate Pharmaceuticals (E); Pammy Subramony, Eyegate Pharmaceuticals (E); Michael A. Patane, Eyegate Pharmaceuticals (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 449. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Manzo, Peyman Moslemy, Begona Ruiz-Perez, Fengqui Fan, Lydia Mbocha, Will Schubert, Phil Isom, Tracy Dowie, Pammy Subramony, Michael A. Patane; Design and Optimization of a Transscleral Iontophoresis Applicator for Delivering Biologics to the Anterior and Posterior Segments. Invest. Ophthalmol. Vis. Sci. 2012;53(14):449.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To develop a transscleral iontophoresis applicator capable of delivering biologics to the anterior and posterior segments.

Methods: : The engineering designs and testing focused on optimizing conductivity, buffering capacity, product stability, and minimizing drug volume requirements. Multiple biocompatible conductive matrices were prepared and evaluated in the ocular iontophoresis applicator drug reservoir. The devices were loaded with Cytochrome C (CytC, 12.4 kDa globular protein) in H2O and tested ex vivo via anodal iontophoresis in a Franz cell apparatus with phosphate buffered saline solution in the receptor chamber.For in vivo testing, New Zealand albino rabbits were dosed with CytC using the test devices impregnated with different biocompatible conductive matrices.

Results: : Following iontophoretic transport experiments in rabbits, bioanalytical results revealed that CytC was present in all ocular tissues harvested. The levels of CytC in conjunctiva, sclera, choroid, retina, vitreous, iris and ciliary body, and aqueous humor were quantified by triple-quad MS. The iontophoretic transport efficiency (percent ratio of total delivery to the initial amount of protein in dosing solution) increased from < 0.7% for passive delivery of 40 and 80 mg/mL CytC solutions to > 7% for iontophoresis. The concentration of CytC in the ocular tissues increased directly with the increase in dosing solution concentration from 10 - 40 mg/mL but remained at comparable levels for 80 mg/mL. Initial pH of dosing solution (7.4 vs. 5.0) had no considerable effect on the amount of protein delivered to the ocular tissues. Varying the current intensity (1 - 8 mA) with a fixed 5 min application time enhanced the concentration of CytC in the tested ocular tissues. Likewise, increasing the iontophoretic dose at a fixed current intensity resulted in enhanced delivery of CytC to the ocular tissues.

Conclusions: : The experimental results demonstrate that significant amounts of CytC can be delivered non-invasively into all rabbit ocular tissues using a novel transscleral iontophoresis ocular applicator.

Keywords: development 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×